CLINICAL STUDY PROTOCOL
Study Title: A Phase 3 Randomized Study  to Evaluate the Safety  and Antiviral 
Activity  of Remdesivir (GS-5734™) in Participants with Moderate 
COVID -
19 Compared to Standard of Care Treatment
Sponsor: Gilead Sciences, Inc.
333 L akeside Drive
Foster City , CA 94404
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:147753
2020-000842-32
[STUDY_ID_REMOVED]
Indication: COVID -
19
Protocol ID: GS-US-540-5774
Contact Information: The medical monitor name and contact information will be 
provided on the Key  Study  Team Contact List.
Protocol 
Version/Date:Original : 24February  2020
Amendment 1.0 15March 2020
Amendment 2.0 29April 2020
This study  will be conducted under US Food & Drug Administration I ND regulations 
(21
CFR Part 312); however, sites located in the European Economic Area and Switzerland 
arenot included under the IND and are considered non- IND sites.
CONFIDENTIALITY STATEMENT
The information contained in this document, particularly unpublished data, is the propert y or 
under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, 
potential investigator, or consultant, for review b y you, your staff, and an applicable 
Institutional Review Board or Independent Ethics Committee. The information is only  to be 
used by  you in connection with authorized clinical studies of the investigational drug 
described in the protocol. You wil l not disclose any of the information to others without 
written authorization from Gilead Sciences, Inc., except to the extent necessary  to obtain 
informed consent from those persons to whom the drug may  be administered.
(rJ GILEAiJ 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 2 29 April 2020TABLE OF CONTENTS
TABLE OF CONTENTS .............................................................................................................................................. 2
LIST OF IN- TEXT TABL ES........................................................................................................................................ 4
PROTOCOL SYN OPSIS .............................................................................................................................................. 5
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 10
1. INTRODUCTION .............................................................................................................................................. 12
1.1. Background ............................................................................................................................................ 12
1.2. Remdesivir (RDV, GS -5734) ................................................................................................................. 12
1.2.1. General Information ............................................................................................................. 13
1.2.2. Preclinical Pharmacology and Toxicology ........................................................................... 13
1.3. Rationale for This Study ........................................................................................................................ 13
1.4. Rationale for Dose Selection of Remdesivir .......................................................................................... 14
1.4.1. Pediatric Dosing ................................................................................................................... 15
1.5. Risk/Benefit Assessment for the Study .................................................................................................. 16
1.6. Com pliance ............................................................................................................................................ 17
2. OBJECTIVES ..................................................................................................................................................... 18
3. STUDY DESIGN ................................................................................................................................................ 19
3.1. Endpoints ............................................................................................................................................... 19
3.2. Study Design .......................................................................................................................................... 20
3.3. Study Treatments ................................................................................................................................... 21
3.4. Duration of Treatment ............................................................................................................................ 21
3.5. Discontinuation Criteria ......................................................................................................................... 21
3.6. End of Study ........................................................................................................................................... 22
3.7. Post Study Care ...................................................................................................................................... 22
4. SUBJECT POPULATION .................................................................................................................................. 23
4.1. Number of Subjects and Subject Selection ............................................................................................ 23
4.1.1. Subject Replacement ............................................................................................................ 23
4.2. Inclusion Criteria .................................................................................................................................... 23
4.3. Exclusion Criteria ................................................................................................................................... 23
5. INVESTIGATIONAL MEDI CINAL PRODUCTS ........................................................................................... 25
5.1. Randomization, Blinding, and Treatment Codes Access ....................................................................... 25
5.1.1. Randomization ..................................................................................................................... 25
5.1.2. Blinding ................................................................................................................................ 25
5.2. Description and Handling of Remdesivir ............................................................................................... 25
5.2.1. Form ulation .......................................................................................................................... 25
5.2.2. Packaging and Labeling ....................................................................................................... 25
5.2.3. Storage and Handling ........................................................................................................... 25
5.3. Dosage and Administration of Remdesivir ............................................................................................ 26
5.4. Accountability for Investigational Medicinal Product ........................................................................... 26
5.4.1. Investigational Medicinal Product Return or Disposal ......................................................... 26
5.5. Prior and Concomitant Medications ....................................................................................................... 27
6. STUDY PROCEDURES .................................................................................................................................... 28
6.1. Subject Enrollment and Treatment Assignment ..................................................................................... 28
6.2. Pretreatment Assessments ...................................................................................................................... 28
6.2.1. Screening Visit ..................................................................................................................... 28
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 3 29 April 20206.2.2. Baseline/Day 1 Assessments ................................................................................................ 29
6.3. Daily Study Assessments ( Days 2 -14)................................................................................................... 30
6.4. Additional Assessments ......................................................................................................................... 30
6.5. Day 28 Follow  up Assessment (± 5 Days) ............................................................................................. 31
6.6. Clinical Laboratory Assessments ........................................................................................................... 31
6.7. Physical Examination ............................................................................................................................. 32
6.9. Ordinal Scale .......................................................................................................................................... 32
6.10. Post-treatm ent Assessments ................................................................................................................... 33
6.11. Assessments for Early Discontinuation from Study ............................................................................... 33
6.11.1. Criteria for Discontinuation of Study Treatment .................................................................. 33
6.12. End of Study ........................................................................................................................................... 34
6.13. Post Study Care ...................................................................................................................................... 34
6.14. SampleDisposition and Storage (Non -PK Samples) ............................................................................. 34
7. ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 35
7.1. Definitions of Adverse Events and Serious Adverse Events .................................................................. 35
7.1.1. Adverse Events ..................................................................................................................... 35
7.1.2. Serious Adverse Events ........................................................................................................ 35
7.2. Assessment of Adverse Events and Serious Adverse Events ................................................................. 36
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 36
7.2.2. Assessment of Severity ........................................................................................................ 37
7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events ....................................................................................................................................... 37
7.3.1. Requirements for Collection Prior to Study Drug Initiation ................................................. 37
7.3.2. Adverse Events ..................................................................................................................... 37
7.3.3. Serious Adverse Events ........................................................................................................ 37
7.3.4. Electronic Serious Adverse Event (eSAE) Reporting Process ............................................. 38
7.4. Gilead Reporting Requirements ............................................................................................................. 38
7.5. Clinical Laboratory Abnormalities and Other Abnormal Asse ssments as Adverse Events or 
Serious Adverse Events .......................................................................................................................... 39
7.6. Special Situations Reports ...................................................................................................................... 39
7.6.1. Definitions of Special Situations .......................................................................................... 39
7.6.2. Instructions for Reporting Special Situations ....................................................................... 40
8. STATISTICAL CONSIDER ATIONS ................................................................................................................ 43
8.1. Analysis Objectives and Endpoints ........................................................................................................ 43
8.1.1. Analysis Objectives .............................................................................................................. 43
8.1.2. Primary Endpoint ................................................................................................................. 43
8.1.3. Secondary Endpoints ............................................................................................................ 43
8.1.4. Other Endpoints of Interest .................................................................................................. 43
8.2. Planned Analyses ................................................................................................................................... 44
8.2.1. Interim Analysis ................................................................................................................... 44
8.2.2. Primary Analysis .................................................................................................................. 44
8.2.3. Part A Analysis ..................................................................................................................... 44
8.2.4. Final Analysis ....................................................................................................................... 44
8.3. Analysis Conventions ............................................................................................................................. 45
8.3.1. Analysis Sets ........................................................................................................................ 45
8.3.2. Data Handling Conventions ................................................................................................. 45
8.4. Dem ographic and Baseline Characteristics Analysis ............................................................................. 46
8.5. Efficacy Analysis ................................................................................................................................... 46
8.5.1. Primary Analysis .................................................................................................................. 46
8.5.2. Secondary Analyses ............................................................................................................. 46
CCI
CCI-
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 4 29 April 20208.6. Safety Analysis ....................................................................................................................................... 47
8.6.1. Exten t of Exposure ............................................................................................................... 47
8.6.2. Adverse Events ..................................................................................................................... 47
8.6.3. Laboratory Evaluations ........................................................................................................ 47
8.8. Adjustments for Multiplicity .................................................................................................................. 48
8.9. Sample Size ............................................................................................................................................ 48
8.10. Data Monitoring Committee .................................................................................................................. 49
9. RESPONSIBILITIES .......................................................................................................................................... 50
9.1. Investigator Responsibilities .................................................................................................................. 50
9.1.1. Good Clinical Practice .......................................................................................................... 50
9.1.2. Financial Disclosure ............................................................................................................. 50
9.1.3. Institutional Review Board/Independent Ethics Committee Revie w and 
Approval ............................................................................................................................... 50
9.1.4. Informed Consent (or Assent) .............................................................................................. 50
9.1.5. Confidentiality ................................................................
...................................................... 51
9.1.6. Study Files and Retention of Records .................................................................................. 51
9.1.7. Case Report Forms ............................................................................................................... 52
9.1.8. Investigator Inspections ........................................................................................................ 53
9.1.9. Protocol Compliance ............................................................................................................ 53
9.2. Sponsor Responsibilities ........................................................................................................................ 53
9.2.1. Protocol Modifications ......................................................................................................... 53
9.2.2. Study Report and Publications ............................................................................................. 53
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 54
9.3.1. Payment Reporting ............................................................................................................... 54
9.3.2. Access to Information for Monitoring .................................................................................. 54
9.3.3. Access to Information for Auditing or Inspections .............................................................. 54
9.3.4. Study Discontinuation .......................................................................................................... 54
10. REFERENCES ................................................................................................................................................... 55
11. APPENDICES .................................................................................................................................................... 56
Appendix 1. Investigator Signature Page .................................................................................................... 57
Appendix 2. Study Procedures Table .......................................................................................................... 58
Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................... 59
LIST OF IN -TEXT TABL ES
Table 1. Data Entry Requirements When Only One Result of Multiple Results Is Recorded 
for a Given Day ...................................................................................................................... 32
CCI
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 5 29 April 2020PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Study Title : A Phase 3 Randomized Study  to Evaluate the Safety  and 
Antiviral Activity  of Remdesivir (GS -5734TM) in Participants 
with Moderate COVID -19 Compared to Standard of Care 
Treatment
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:147753
2020-000842-32
[STUDY_ID_REMOVED]
Study Centers Planned: Up to approximately  160 centers globall y
Objectives: The purpose of this stud y is to provide remdesivir (RDV) to 
participant s with moderate COVID -19.
The primary  objective of this study  is as follows:
To evaluate the efficacy of 2RDV regimens compared to 
standard of care (SOC), with respect to clinical status 
assessed b y a 7 -point ordinal scale on Day 11
The secondary  objective of this study  is as follows: 
To evaluate the safet y and tolerability  ofRDV compared to 
SOC
Study Design: This is a Phase 3 randomized, open- labeled, multi-c enter study  
RDV therap y in participants with moderate COVID -19.
The study  will be conducted in two parts. In Part A, 
approximately  600 participants who meet all eligibility  criteria 
may be randomized in 1:1:1 ratio into one of the following 
treatment groups:
Treatment Group 1: continued SOC therapy  together with 
intravenous ( IV)RDV 200 mg on Day  1 followed by  IV RDV 
100mg on Day s 2, 3, 4, and 5
Treatment Group 2:continued SOC therapy  together with IV 
RDV 200 mg on Day  1 followed by  IV RDV 100 mg on Day s 2, 
3, 4, 5, 6, 7, 8, 9, and 10
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 6 29 April 2020Treatment Group 3:continued SOC therapy
Part B will be enrolled after enrollment to Part A is complete. In 
Part B, an additional approximately 1000 participants who meet 
all of the eligibility  criteria may  receive:
Extension Treatment Group: continued standard of care 
therap y together with IV RDV 200 mg on Day  1 followed by  IV 
RDV 100 mg on Day s 2, 3, 4, 5, 6, 7, 8, 9, and 10
If Treatment Group 1 of Part A is selected for Part B, or if 
treatment for 5 day s isselected in a study  of more severe 
disease, 
all participants in the Extension Treatment Group and 
all new participants will be reassigned to receive treatment for a 
total of 5 days.National and local regulatory  authorities will be 
informed.
Participants in Part A of the study  will be the primary  efficacy  
population. Participants enrolled in Part B, will have data 
reported descriptivel y at study  completion.
Number of Subjects 
Planned:Approximately  1600
Target Population: Participants 
with moderate COVID -19
Duration of Treatment: The duration of treatment with RDV will be up to 10 day s
Diagnosis and Main 
Eligibility  Criteria:Participants with COVID -19confirmed b y polymerase chain 
reaction ( PCR) w ho meet the following criteria:
Willing and able to provide written informed consent 
(age ≥18) or assent (age ≥12 to <18, where locally  and 
nationally  approved) prior to performing study  procedures
Hospitalized and requiring medical care fo r COVID -19
SpO 2>94% on room air at screening
Radiographic evidence of pulmonary infiltrates
Study  Procedures/
Frequency :At Screening , after the participant has provided informed 
consent or assent , demographic and baseline characteristics, 
medical history , and concomitant medications will be 
documented. Vital signs including temperature, respiratory  rate, 
and SpO 2will be recorded. Radiographic imaging will be 
performed if not alread y available. SARS -CoV -2 testing b y PCR 
will be performed; if this t
esting has been performed within the 
previous 4 days, no repeat testing is required.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 7 29 April 2020If safety  laboratory  results from the screening day  are not 
alread y available, laboratory  testing including alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) , 
serum creatinine, and creatinine clearance will be performed 
according to local practice.
In Part A, after screening procedures, eligible participants will 
be randomized into 1 of the 3 treatment groups in a 1:1:1 ratio to 
receive:
Treatment Group 1:continued SOC therapy  together with IV 
RDV 200 mg on Day  1 followed by  IV RDV 100 mg on Day s 2, 
3, 4, and 5
Treatment Group 2:continued SOC therapy  together with IV 
RDV 200 mg on Day  1 followed by  IV RDV 100 mg on Day s 2, 
3, 4, 5, 6, 7, 8, 9, and 10
Treatment Group 3:continued SOC therapy
In Part B, a
fter screening procedures, eligible participants will be
assigned to receive:
Extension Treatment Group: continued standard of care 
therap y together with IV RDV 200 mg on Day  1 followed by  IV 
RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 as determined 
by review of the data. Treatment may  be reduced to a total of 
5days following anal ysis of the data from Part A.
The date of randomization will be considered Day 1 and all 
participants randomized to rece ive RDV should receive their 
initial dose on Day 1.
On study  Day s 1 through 14 or until discharge, whichever is 
earlier, 7-point ordinal scale of clinical status, vital signs 
including respiratory  status will be measured and adverse events 
(AEs) and concomitant medications will be documented. 
Laboratory  testing will be performed according to SOC practice 
with results for white blood cell count, hemoglobin and/or 
hematocrit , platelets, creatinine, creatinine clearance, glucose, 
total bilirubin, ALT, AST ,and an y SARS -CoV -2 testing being 
reported to the Sponsor. 
In addition, even if not performed as standard of care, white 
blood cell count, hemoglobin and/or hematocrit , platelets, 
creatinine, creatinine clearance , glucose, total bilirubin, A LT, 
AST will be performed at Day s 1, 3, 5, 8, 10, and 14 or until 
discharge, whichever is earlier.
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-540-5774 
Gilead Sciences, Inc. 
Test Product, Dose, and 
Mode of Administration: 
Reference Therapy, Dose, 
and Mode of 
Administration: 
Criteria for Evaluation: 
Safety: 
Efficacy: 
Statistical Methods: 
CONFI DENT IAL FINAL 
Amendment 2.0 
Additional SARS-Co V -2 testing may be conducted at selected 
sites. At partic ipating sites, nasopharyngea l swab samples will 
be collected at Days 1, 3, 5, 8, 10, and 14, sent to a centra l 
laboratory, and assayed using quant itative reverse transcr iptase 
PCR to quant ify SARS-CoV-2 viral load. Pretreat ment and 
posttreatment samples with detectab le SARS-CoV-2 may be 
sequenced for resistance monitoring of the viral polymerase 
gene . 
Remdesivir (GS-5734) for inject ion, 100 mg, for IV 
administrat ion 
Treatment with SOC accord ing to local pract ice 
Incid ence of treatment-emergent AEs and treatment-emergent 
clinical laboratory abnonna lities 
Clinical status assessed by a 7-po int ordinal scale on Day 11 
The primary endpo int will be analyzed using a proport ional odds 
model. The null hypothes is being tested is whether the odds of 
improvement on the ordina l scale is the same for either RDV or 
SOC treatment groups (ie, whether the co1mnon odds ratio is 
equal to 1 ). The odds ratio and 95% confidence interval will be 
prov ided. 
Treatment-e mergent AEs and laboratory abnonna lities will be 
smmnariz ed using descr iptive statistics and listed by subject. 
Page 8 29 April 2020 
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-540-5774 
Gilead Sciences, Inc. 
Sample Size: FINAL 
Amendment 2.0 
In Part A, a total of approx imately 600 partic ipants will be 
randomized in a 1: 1: 1 ratio to 3 groups (200 participants per 
group) . 
A sample size of 200 participants in each of 2 groups achieves 
> 85% power to detect an odds ratio of 1.8 using a two-si ded 
alpha level of 0.05. 
The sample size of Part B is based on the anticipated need for 
RDV and current trends in the COVID-19 epidemic. 
This study w ill be conducted in accor dance with the guidelines of Good Clinical Practice (GCP) 
inclu ding arch iving of essent ial documents . 
CONFI DENT IAL Page 9 29 April 2020 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 10 29 April 2020GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
AE adverse event
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC tau area under plasma concentration -time curve over dosing interval
CDC Centers for Disease Control and Prevention
CoV Coronavirus
CRF case report form
CSR clinical study report
DAIDS Division of AIDS
DMC data monitoring committee
EBOV Ebola virus
eCCGs eCRF Completion Guidelines
eCRF electronic case report form
EDC electronic data capture
EU European Union
FAS Full Analysis Set
FDA Food and Drug Administration
GCP Good Clinical Practice
Gilead Gilead Sciences
HIV human immunodeficiency virus
IB investigator’s brochure
ICH International Conference on Harmoni sation (of Technical Requirements for 
Pharm aceuticals for Human Use)
IDMC independent data monitoring committee
IEC independent ethics committee
IRB institutional review board
IUD intrauterine device
IV intravenous
LLOQ lower limit of quantitation
LPV lopinavir
LPV/RTV -IFNb LPV/RTV + interferon -beta
MERS Middle East Respiratory Syndrome
OAT organic anion transporter
PBPK physiologically -based pharmacokinetic
PCR polymerase chain reaction
PK pharmacokinetic(s)
PT preferred term
PVE Pharm acovigilance and Epidemiology
RDV remdesivir
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 11 29 April 2020RNA ribonucleic acid
RT reverse transcriptase
qRT-PCR quantitative reverse transcriptase polymerase chain reaction
RTV ritonavir
SAE serious adverse event
SARS Severe Acute Respiratory Syndrome
SBECD sulfobutylether β -cyclodextrin sodium
SOC system organ class
SOP standard operating procedure
SUSAR suspected unexpected serious adverse reaction
TEAE treatment -emergent adverse event
TM test method
ULN upper limit of normal
US United States
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 12 29 April 20201. INTRODUCTION
1.1. Background
In December 2019, a series of pneumonia cases of unknown cause emerged in Wuhan, 
Hubei, China. Sequencing anal ysis from the patients’ respiratory  tract samples indicated a novel 
coronavirus (CoV), which was named COVID -19. As of 23 February  2020, more than 
78,000 confirmed cases have been identified in Wuhan, other provinces in China, and in multiple 
countries outside China {World Health Organisation (WHO) 2020 }. More than 2400 deaths 
associated with COVID -19 have been reported, making COVID- 19 a major health emergency .
Antiviral drugs that are being evaluated as potential treatments for COVID -19 include 
lopinavir/ritonavir ( LPV/RTV ; used in the treatment of HIV infection) and re mdesivir (RDV, 
GS-5734™). In a stud y of Severe Acute Respiratory S yndrome (SARS), a significant reduction 
in acute respiratory  distress sy ndrome/mortalit y was observed in 41 patients treated with the 
combination of LPV/RTV , compared with 111 patients recei ving monotherapy  ribavirin (2.4 % 
vs 28.8%, p  0.001). However, the use of historical control data does not allow for a reliable 
estimation of efficacy . Additionally , LPV/RTV has multiple known adverse reactions such as 
prolonged QT interval, severe gastr ointestinal reactions, abnormal blood glucose, pancreatitis, 
hepatic impairment, and elevated blood lipids. I t has multiple drug -to-drug interactions with 
many commonly  used drugs in clinical practice; thus, its clinical safet y is not determined. 
Remdesivi r shows potent in vitro activity  against the human pathogenic CoVs Middle East 
Respiratory  Syndrome (MERS) -CoV and SARS -CoV in multiple relevant human cell ty pes. In a 
mouse model of MERS- CoV infection, both prophy lactic and therapeutic RDV significantly  
improved pulmonary  function and reduce lung viral loads and severe lung pathology  compared 
with vehicle control animals. I n contrast, prophylactic L PV/RTV + interferon -beta 
(LPV/RTV -IFNb ) slightly  reduced viral loads without impacting other disease paramete rs. 
Therapeutic LPV/RTV -IFNb improves pulmonary function but did not reduce virus replication 
or severe lung pathology  {Sheahan 2020}.
The evaluation of the safety  and potential efficacy of RDV in people with COVID
-19 is urgentl y 
needed.
1.2. Remdesivir (RDV, GS -5734)
Remdesivir is being developed by  Gilead Sciences, I nc. (Gilead) and is formulated for
intravenous (IV) administration .
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 13 29 April 20201.2.1. General Information
Remdesivir is a nucleotide prodrug that is intracellularly  metabolized into an analog of adenosine 
triphosphate that inhibits v iral RNA poly merases and has broad spectrum activity  against 
members of the filoviruses (eg, Ebola virus [EBOV], Marburg virus [MARV]), CoVs
(eg,SARS -CoV , MERS -CoV), and param yxoviruses (eg, respiratory syncytial virus [RSV], 
Nipah virus, and Hendra virus ).For further information on RDV, refer to the current 
investigator’s brochure (IB) for RDV. Information in the IB includes:
Nonclinical pharmacokinetic (PK) and in vitro metabolism
Nonclinical pharmacology  and toxicology
Clinical experience
Additional re levant information regarding RDV are described below.
1.2.2. Preclinical Pharmacology and Toxicology
Recent results from initial in vitro testing performed at the China CDC in collaboration with 
Gilead showed that RDV has potent antiviral activity against SARS -CoV-2in Vero cells 
(EC 500.137 μM).  I n another study  conducted by  the Wuhan Institute of Virology , RDV also 
showed in vitro activity  against SARS -CoV -2in Vero cells (EC 50 0.77 μM) {Wang 2020}. 
Gilead notes that the study  from the Wuhan Institute of Virology  was conducted externally  with 
drug not supplied by  Gilead. Researchers in the United States ( US)and China are continuing to 
test RDV against clinical isolates of SARS -CoV - 2using drug supplied by  Gilead in multiple 
relevan t cell ty pes that are known to more efficiently  metabolize RDV into its active triphosphate 
form compared with Vero cells.
1.3. Rationale for This Study
There is currently no approved treatment available for COVID -19 infection. The 
recommendation for using RDV as treatment of COVID -19is based on the in vitro and in vivo 
activity  of RDV against SARS -CoV -2and other the human highl y pathogenic CoVs, 
MERS -CoV and SARS -CoV. 
Remdesivir has acceptable nonclinical tolerabilit y and saf ety profiles and exhibits in vivo 
prophy lactic and therapeutic efficacy  against SARS -CoV and MERS- CoV infection in mice and 
MERS -CoV infection in rhesus monkey s. In addition, RDV has been shown to be safe and 
tolerable ,with a safet y database of over 500 i ndividuals who have received RDV to date. Key  
attributes of the RDV nonclinical and clinical profile supporting its use for emergency  treatment 
of COVID -
19are as follows:
Initial i n vitro testing performed at the China CDC in collaboration with Gilead sho wed that 
RDV has potent antiviral activity  against SARS -CoV -2in Vero cells (EC 50 0.137 μM). 
Remdesivir has also shown potent in vitro activity  against the human pathogenic CoVs
MERS -CoV and SARS -CoV in multiple relevant human cell types.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 14 29 April 2020The PK profile of RDV in nonhuman primates (NHPs) and other relevant animal species 
indicates high and persistent levels of pharmacologically  active nucleoside triphosphate 
metabolite in peripheral blood mononuclear cells (PBMCs), supporting once dail y IV 
administration as a 30 -minute infusion.
Remdesivir demonstrated prophy lactic and therapeutic efficacy  in a mouse model of 
SARS -CoV pathogenesis. Administration of 25 mg/kg RDV subcutaneously twice daily  
beginning 1 day before or 1 day  after SARS -CoV inoculation resulted in significantly  
reduced lung viral load and improved clinical signs of disease as well as lung function 
{Sheahan 2017}.
Inamouse model ofMERS -CoV pathogenesis, both prophy lactic andtherapeutic 
administration of
25mg/kg RDV subcutaneousl ytwice daily improved pulmonary function
andreduced lung viral loads and severe lung pathology .Incontrast, prophy lactic
LPV/RTV -IFNb slightl yreduced viral loads without impacting other disease parameters.
Therapeutic L PV/RTV -IFNb improved pulmonary function but did not reduce virus 
replication or severe lung pathology  {Sheahan 2020 }.
Remdesivir also showed prophy lactic and therapeutic efficacy  in MERS -CoV -infected rhesus 
monkey s of Indian origin. Administration of RDV at 10 mg/kg (see RDV IB) or 5 mg/kg 
once dail y for 7 days using IV bolus injection beginning 1 day prior to MERS -CoV 
inoculation resulted in a significant reduction of clinical scores, clinical signs of respiratory  
disease, and viral RNA levels compared to vehicle- treated animals. Therapeutic RDV 
treatment of 5 mg/kg once daily  using IV bolus injection initiated 12 hours post - inoculation 
also resulted in reduced clinical signs, reduced virus replication in the lungs, and decreased 
presence and severit y of lung lesions {De Wit 2020 }.
Remdesivir has a favorable clinical safet y profile based on approximately
 500 individ ualswho 
received RDV primaril y as health y volunteers in Phase 1 studies and individuals with acute 
EBOV infection.
The design of enrollment in two parts will allow the optimal duration of treatment to be 
determined and then allow continued access to RDV and data collection for eligible participants. 
In addition, further safet y data will be obtained.
1.4.
Rationale for Dose Selection of Remdesivir
The proposed regimen for the treatment of established CoV infection, including SARS -CoV and
MERS -CoV , is as follows: single RDV 200 mg IV loading dose on Day  1 of treatment followed 
by 100 mg IV once -daily maintenance doses for a total of up to 10 day s of dosing. The proposed 
dosing regimen is based on efficacy  studies in MERS -infected rhesus monkey s treated with RDV 
(Studies PC -
399-2037 and PC-399- 2038) and based on clinical safet y data in approximately 
500patients including healthy  volunteers and individuals with acute EBOV infection.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 15 29 April 2020In the nonclinical studies, RDV was administered at 10 mg/kg (Study  PC-399-2038) or 5 mg/kg 
(Study  PC-399- 2037) once dail y for 7 days using IV bolus injection beginning either 1 day  prior 
to or 12 hours after (5 mg/kg onl y) MERS -CoV inoculation. 
Remdesivir treatment was 
efficacious at reducing viral titers in the lung and alleviating cli nical disease signs (RDV IB ; {De 
Wit 2020 }). Toxicology studies in cynomolgus monkeys and rats and safety and PK studies in 
healthy  volunteers support the safet y of the proposed dose . Overall, RDV has a favorable PK and 
safet y profile that supports evaluation of a 200 mg loading and a 100 mg daily  dose that has 
potential to be efficacious in adult patients with 
COVID -19.
The optimal duration of therap y with RDV remains unknown. However, other agents for acute 
antivir al infection, for example 
oseltamivir phosphate {TAMIFLU® 2019 }, have treatment 
courses ranging from 5 day s duration. There is considerable potential patient benefit and societal 
benefit in identify ing the minimum duration that will be effective .
1.4.1. Pediatric Dosing
As with the adult dose, the efficacious dose of RDV against SARS- CoV -2 remains to be 
established. 
Dose selection of RDV in EBOV infected pediatric patients was informed by  a ph ysiologicall y-
based pharmacokinetic (PBPK) model implemented in SimCYP (v.17, Certara). Briefly , a PBPK 
model was developed to characterize the PK of RDV and the primary  circulating nucleoside 
metabolite, GS -441524, in adults. The model was verified based on its ability  to describe the 
mean and variability  of the a dult exposures using data from the RDV Phase 1 program 
(GS-US-399- 1812). The adult PBPK model was subsequently  used to simulate steady -state 
pediatric (age range 0 to 18 years) exposures (AUC tau), accounting for age -dependent changes in 
organ volume/size ( liver and kidney ), esterase expression, plasma protein binding, and organ 
blood flow.
These simulations do not account for diminished liver or kidney  function due to SARS -CoV -
2 
infection and/or COVID -19 progression because the impact of infection/disease p rogression on 
the PK of RDV and GS -441524 is currentl y unknown.
The results of these simulations indicate: 
For pediatric patients with body  weight ≥ 40 kg, a 200 mg loading dose followed by  100 mg 
once -daily maintenance doses of RDV (ie, the adult dosage regimen) should be administered. 
Use of the adult dose in these pediatric patients is expected to maintain exposures of both RDV 
and GS -441524 generally  within those expected at the therapeutic doses and which were 
previously  observed to be well tolerated in healthy  volunteers.   
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 16 29 April 20201.5. Risk/Benefit Assessment for the Study
Potential risks associated with the study  include unknown adverse events (AEs) and laboratory  
abnormalities. Although not specificall y evaluated yet, adolescents with COVID -19 who receive 
RDV are expected to have similar safety profile as adults; no additional safety monitoring is 
required for adolescent participants and no dose adjustments are required. No differing safet y 
profile has been reported for the adolescents with EBOV who received RD V in clinical trials. 
Accordingl y, the risk:benefit profile, described below, is the same for adolescents and adults.
A pertinent specific risk for participa ntsin this study  is the potential for transient ,Grade ≤ 2, 
treatment -emergent elevations in alanine aminotransferase ( ALT )and aspartate aminotransferase 
(AST), which were observed after multiple daily  RDV administrations in Studies 
GS-US-399- 1954 and GS -US- 399-5505.
To date in human studies, no serious adverse events ( SAEs ) have occurred in healthy  individuals 
who have received at least 1 dose of RDV. Remdesivir has been tested in healthy volunteers as a 
single ascending dose over a dose range of 3 to 225 mg and in a multi -dose study  of 150 mg for 
up to 14 day s and at 200 mg loading dose followed by 100 mg for a total of 10 day s. 
In nonclinical animal studies, toxicity  findings were consistent with dose
-dependent and 
reversible kidney  injury  and dy sfunction. The clinical significance of the nephrotoxicity  noted in 
animal species is unknown
.The e tiology  of reversible kidney  injury  observed in rats is consistent 
with the ability  of rat renal organic anion transporters (OATs), but not human OATs, to 
efficientl y interact with blood metabolites of RDV , particularl y GS -704277. This effect may  lead 
to proportionally  higher intracellular accumulation of drug metabolites in renal rat tubules, 
leading to kidney  injury .
The 200 mg loading dose with 8 g of sulfobut ylether β -cyclodextrin sodium (SBECD) on Day 1 
will be followed by  100 mg of RDV each day  for 4 or 9 day s with 4 g of SBECD, which is 
within the range of daily  SBECD administration considered safe in humans. A total of 
250mg/kg/day  of SBECD is considered safe b y the European Medicines Agency  and is therefore 
safe for people with weight over 32 kg. The 100 mg dose prepared in 0.9% saline will be 
hypertonic relative to human serum osmolality  but approaches the normal phy siological osmolar 
range for humans. The RDV regimen consisting of a loading dose of 200 mg followed by  RDV 
100 mg dail
y for up to 9 day s is not anticipated to pose a safety  risk to participants enrolled in 
this study .
There are currently  no data available on the interaction of RDV and other investigational agents. 
Administering RDV concurrent with other investigational anti -CoV agents m ay lead to 
antagonism orsynergy  or have no effect.
The risk mitigation strategy  for this study  includes r estriction of the study  population to those 
without a history  of significant renal or hepatic disease:
Exclusion of participants with AL T > 5 upper limit of normal ( ULN )
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 17 29 April 2020Exclusion of participants with an estimated glomerular filtration rate (eGFR) < 50mL/min
Exclusion of coadministration of other investigational agents against COVID -19
Serum chemistry  assessments, including liver function testing, will be closely  monitored 
during the stud y period.
There are currently  no investigational agents with demonstrated clinical efficacy  or approved 
treatments for COVID -19. The timely  evaluation of a safe and effective antiviral agent that 
works by  directl y and selectivel y blocking the virus replication and is broadly efficacious against 
SARS -CoV -
2addresses a serious unmet medical need. In consideration of the information 
included in this protoc ol, the overall risks to participant s are outweighed b y the potential benefits 
of RDV experimental therap y for the treatment of COVID -19. T he benefit -risk balance for this 
study  is considered positive.
1.6. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 18 29 April 20202. OBJECTIVES
The purpose of this stud y is to provide RDV to participant s with moderate COVID -19.
The primary  objective of this study  is as follows:
To evaluate the efficacy of 2RDV regimens compared to standard of care (SOC), with 
respect to clinical status assessed by  a 7-point ordinal scale on Day  11
The secondary  objective of this study  is as follows:
To evaluate the safet y and tolerability  ofRDV compared to SOC
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 19 29 April 20203. STUDY  DESIGN
Part A of t his is a Phase 3 randomized, open -labeled, multi- center study  RDV therap y in adult 
participants with moderate COVID -
19. Part B is a single group multicenter study  of RDV in 
participants with moderate COVID -19 infection. All partici pants will continue to receive SOC
therap y according to local guidelines. Participants randomized to receive RDV will receive this 
in addition to their other care.
3.1. Endpoints
The primary  endpoint of this study  is:
Clinical status assessed by a 7 -point ordin al scale on Day  11
The secondary  endpoint of this study  is:
The proportion of participants with treatment emergent adverse events 
Other endpoints of interest are:
The proportion of participants 
with negative SARS -CoV -2 poly merase chain reaction (PCR)
Time to clinical improvement (day s): clinical improvement is defined as a ≥ 2-point 
improvement in clinical status (7-
point ordinal scale) from Day  1 
Time to ≥ 1 -point improvement (day s) from baseline clinical status
Time to recovery : defined as an improvement in clinical status from a baseline score of 2 
through 5 to a score of 6 or 7, or an improvement from a baseline score of 6 to a score of 7
Time to modified recovery : defined as an improvement in clinical status from a baseline 
score of 2 through 4 to a score of 5, 6, or 7, or an improvement from a baseline score of 5 to a 
score of 6 or 7, or an improvement from a baseline score of 6 to a score of 7
Time to room air: defined as an improvement in clinical status from a baseline score of 2 
through 4 to a score of 5, 6, or 7
Duration of ox ygen therapy (day s)
Shift in ox ygen support status from baseline
Duration of hospitalization (day s)
All cause mortalit y at Day 28
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 20 29 April 2020The proportion of participants in the Extension Treatment Group with treatment emergent 
adverse events
3.2. Study Design
Part A of this is a Phase 3 randomized, open- labeled, multi -center study  RDV therap y in
participants with moderate COVID -
19.Eligible participants will be randomized in equal 
proportions to 1 of 3 treatment groups. No stratification will be performed. Part B is a single 
group multicenter study  of RDV in participants with 
moderate COVID -19 infection. 
CCII 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 21 29 April 20203.3. Study Treatments
In Part A, a pproximately  600 participants who meet all eligibility  criteria may  be randomized in 
a 1:1:1 ratio into 1of the following treatment groups:
Treatment Group 1: continued SOC therapy  together with IV RDV 200 mg on Day  1 followed 
by IV RDV 100 mg on Day s 2,3, 4, and 5
Treatment Group 2:continued SOC therapy  together with IV RDV 200 mg on Day  1 followed 
by
 IV RDV 100 mg on Day s 2, 3, 4, 5, 6, 7, 8, 9, and 10
Treatment Group 3:continued SOC therapy
In Part B ,an additional approximately  1000 participants who meet all of the eligibility  criteria 
may receive:
Extension Treatment Group: continued standard of care therap y together with I V RDV 
200mg on Day  1 followed by  IV RDV 100 mg on Day s 2, 3, 4, 5, 6, 7, 8, 9 , and 10 
unless 
treatment Group 1 of Part A is selected. If treatment for 5 day s is selected, all participants in the 
Extension Treatment G roup and all new participants will be reassigned to receive treatment for a 
total of 5 day s.National and local regul atory  authorities will be informed.
Participants in Part A of the study  will be the primary  efficacy  population. Participants enrolled 
in Part B, will have data reported descriptivel y at study  completion.
3.4. Duration of Treatment
Participants will receive stu dy treatment with RDV for 5 day s (treatment group 1), study  
treatment with RDV for 10 day s (treatment group 2), no RDV (treatment group 3) , or either 5 or 
10 day s (Extension Treatment Group) . If the participant is discharged, RDV treatment will stop 
at that time.
3.5. Discontinuation Criteria
Study  drug dosing in an individual subject will be placed on hold and may be discontinued, 
following a review of all available clinical data by  the medical monitor and discussion with the 
investigator, if any of the foll owing occurs :
Any SAE or ≥ Grade 3 AEsuspected to be related to RDV
Any elevations in ALT > 5 ULN; or ALT > 3 ULN and total bilirubin > 2 ULN, 
confirmed b y immediate repeat testing
Creatinine Clearance < 30mL/min
Discontinuation of study  medication is not a seriousness criterion.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 22 29 April 2020Subjects who discontinue the study  medication should be encouraged to remain in the study  and 
attend study  visits as described in Sections 6.3, 6.4 ,and 6.5.
3.6. End of Study
The end of the stud y will be the last participant’s last observation (or visit).
3.7.
Post Study Care
The long- term care of the participant will remain the responsibility of their pr imary  treating 
physician. Remdesivir is being supplied with curative intent. There is no provision for post -study  
availability .
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 23 29 April 20204. SUBJECT POPULA TION
4.1. Number of Subjects and Subject Selection
In Part A, a pproximately  600 participants will be randomized in a 1:1:1 ratio into 1 of 
3treatment groups. In Part B, up to a pproximately 1000 participants may be assigned into a 
single treatment group. Rescreening may  occur at the investigator’s discretion.
4.1.1. Subject Replacement
Subjects who discontinue prior to the end of stud y will not be replaced .
4.2. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study :
1) Willing and able to provide written informed consent (participants ≥ 18 y ears of age) or 
assen t (participants ≥ 12 and < 18 years of age) prior to performing study  procedures. For 
participants ≥ 12 and < 18 y ears of age, a parent or legal guardian willing and able to provide
written informed consent prior to performing study  procedures
2)Aged ≥ 18 y ears(at all sites), or aged ≥ 12 and < 18 y ears of age weighing ≥ 40 kg (where 
permitted according to local law and approved nationally  and b y the relevant institutional 
review board [ IRB]or independent ethics committee [IEC])
3)SARS -CoV -2infection confirmed by  PCR ≤ 4 days before randomization
4)Currently  hospitalized and requiring medical care for COVID -19
5)SpO 2 >94% on room air at screening
6)Radiographic e vidence of pulmonary infiltrates
7)Men and women of childbearing potential who engage in heterosexual intercourse must agree 
to use protocol specified method(s) of contraception as described i n Appendix 3.
4.3.
Exclusion Criteria
Subjects who me et any of the following exclusion criteria are not to be enrolled in this study :
1)Participation in any other clinical trial of anexperimental agent treatment for COVID -19
2)Concurrent treatment or planned concurrent treatment with other agents with actual or
possible direct acting antiviral activity  against SARS -CoV -2 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 24 29 April 20203) Requiring mechanical ventilation at screening
4) ALT or AST > 5ULN
Note: if per local practice only ALT is routinely measured, exclusion criteria will be 
evaluated on ALT alone
5)Creatinine clearance <50 mL/min using the Cockcroft -Gault formula for participants
≥ 18 years of age {Cockcroft 1976} and Schwartz Formula for participants < 18 y ears of age
6) Positive pregnancy  test (Appendix 3)
7) Breastfeeding woman
8) Known hy persensitivity  to the study  drug , the metabo lites, or formulation excipient
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 25 29 April 20205. INVESTIGA TIONAL  MEDI CINAL  PRODUCTS
5.1. Randomization, Blinding ,and Treatment Codes Access
5.1.1. Randomization
Subjects who meet eligibility  criteria will be randomized in a 1:1:1 ratio to 1 of 3 treatment 
groups on Day  1using an I WRS , and assigned a subject number . Randomization will not be 
stratified.
5.1.2. Blinding
Blinding of treatment assignments o r data will not be performed in this study .
5.2. Description and Handling of Remdesivir
5.2.1. Formulation
Remdesivir for injection , 100 mg, is a preservative- free, white to off -white toyellow, l yophilized 
solid containing 1 00 mg of GS - 5734 that is to be reconstituted with sterile water for injection and 
diluted into 0.9% saline prior to administra tion by  IV infusion.
In addition to the active ingredient, RDV for injection, 1 00 mg, contains the following inactive 
ingredients: betadex sulfobuty l ether sodium (SBECD), water for injection, hy drochloric acid, 
and sodium hy droxide. Hy drochloric acid and sodium hy droxide are used to adjust the 
formulation to a pH of 3.0 to4.0.
5.2.2. Packaging and Labeling
Remdesivir for injection , 100 mg, issupplied as asterile product in a single -use, 30mL Type I 
clear glass vial. Each vial is sealed with a fluoro -resin lam inated rubber stopper and an aluminum 
overseal with a red, plastic flip- off cap.
Remdesivir for injection, 100 mg, shall be labeled to meet all applicable requirements of the 
USFood and Drug Administration (FDA), EU Guideline to Good Manufacturing 
Practic e -Annex 13 (Investigational Medicinal Products), the J -GCP (Ministerial Ordinance on 
Good Clinical Practice for Drugs), as applicable, and/or other local regulations .
5.2.3. Storage and Handling
Remdesivir for injection , 100 mg, should be stored below 30 °C (86 °F) prior to use. Storage 
conditions are specified on the label. Until dispensed for dosing, all vials of study  drugs should 
be stored in a securel y locked area, accessible only to authorized site personnel. 
To ensure the sterility , stability , and proper identification, study  drug(s) should not be stored in a 
container other than the container in which they  were supplied.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 26 29 April 2020Measures that minimize drug contact with the body should alway s be considered during 
handling , preparation, and disposal procedures.
Remdesivir for injection, 100 mg, is recommended to be reconstituted and diluted on the same 
day as administration. Remdesivir for injection, 100 mg, does not contain any  preservative and is 
intended for single -use. Any unused RDV material should be discarded.
5.3. Dosage and Administration of Remdesivir
Remdesivir for injection, 100 mg, will be provided by  Gilead. In Part A, p articipants in 
Treatment 
Groups 1 and 2 will receive RDV 200 mg on Day  1 followed by  IV RDV 100 mg on 
Days 2, 3, 4, and 5. Participants in Treatment G roup 2 will also receive RDV 100 mg on Day s 6, 
7, 8, 9, and 10. In Part B, participants in the Extension Treatment Group will receive RDV 
200mg on Day  1 followed by  IV RDV 100 mg on Day s 2, 3, 4, 5, 6, 7, 8, 9, and 10. If Treatment 
Group 1 of Part A is selected for Part B, or if treatment for 5 day s isselected in a study  of more 
severe disease, all participants in the Extension Treatment Group and all new participants will be 
reassigned to receive treatment for a total of 5 days. Remdesivir treatment will be stopped at 
discharge regardless of the scheduled duration of therap y.Remdesivir will be administered over 
30 minutes where possible.
5.4. Accountability for Investigational Medicinal Product
The investigator is responsible for ensuring adequate accountability  of all used and unused study  
drug. This includes acknowledg ment of receipt of each shipment of study  drug (quantity  and 
condition). 
Each stud y site must keep accountabilit y records that capture :
The date received and quantity  of study  drug kits 
The date, subject number , and the study  drug kit number dispensed
The date, quantit y of used and unused study  drug returned, along with the initials of the 
person recording the information
5.4.1. Investi gational Medicinal Product Return or Disposal
Gilead recommends that used and unused study  drug supplies be destroy ed at the site. If the site 
has an appropriate SOP for drug destruction as determined b y Gilead, the site may destro y used 
(empty  or partiall y empty) and unused study  drug supplies in accordance with that site’s 
approved SOP. A cop y of the site’s ap proved SOP will be obtained for eTMF . If study  drug is 
destroy ed on site, the investigator must maintain accurate records for all study  drug s destroy ed. 
Records must show the identification and quantity  of each unit destroy ed, the method of 
destruction, an d the person who disposed of the study  drug . Upon study  completion, copies of 
the 
study  drug accountability  records must be filed at the site. Another copy  will be returned to 
Gilead. 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 27 29 April 2020If the site does not have an appropriate SOP for drug destruction, used and unused study  drug
supplies are to be sent to the designated disposal facility  for destruction. The study  monitor will 
provide instructions for return.
The study  monitor will review study  drug supplies and associated records at periodic intervals.
For both disposal options listed above, the study  monitor must first perform drug accountability  
during an on- site monitoring visit.
5.5. Prior and Concomitant Medications
Concomitant use of the following is prohibited in participant s receiving RDV :
Traditional herbal treatments including herb sho
-saiko -to (or Xiao -Shai- Hu-Tang)
Investigational agents with putative antiviral activity  for COVID- 19 including approved HIV 
protease inhibitors such as lopinavir/ritonavir , chloroquine, interferon ,etc.
Conc omitant use of investigational agents such as approved HIV protease inhibitors like 
lopinavir/ritonavir
, chloroquine, etc while receiving RDV is prohibited due to lack of evidence 
on additive or sy nergistic effects and potential for an increased risk of tr ansaminase elevations.
Medications will be assessed only  from Day 1prior to enrollment to Day  28or discharge ,
whichever is earlier.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 28 29 April 20206. STUDY  PROCEDURES
The study  procedures to be conducted for each subject enrolled in the study  are presented in 
tabular form in Appendix 2and described in the text that follows. 
The investigator must document any deviation from the protocol procedures and notify  the 
Gilead or contract research organization (CRO).
6.1. Subject Enrollment and Treatment Assignment
Entry  into screening does not guarantee enrollment into the study . In order to manage the total 
study enrollment, Gilead, at its sole discretion, may  suspend screening and/or enrollment at any  
site or 
study -wide at any  time.
6.2. Pretreatment Assessments
6.2.1. Screening Visit
Subjects will be screened within 2days before randomization and dosing to determine eligibility  
for participation in the study . 
Obtain written informed consen tor assent (age ≥12 to <18, where locall y and nationally 
approved)
After the informed consent the following assessments are performed to determine eligibility  
requirements as specified in the inclusio n and exclusion criteria:
Focused medical history  including the following information (eg ,date of first sy mptoms, 
overall s ymptoms, exposure source, demographics, baseline characteristics, allergies and 
medical history
Review and record medications and therapies for this current illness 
Counsel subjects to use adequate birth control methods required during the trial to avoid 
pregnancy
Targeted ph ysical examination including, vital signs (heart rate, temperature, blood pressure), 
body  weight, and height
Documentation of respiratory  status:
Respiratory  Rate
Oxygen supplementation: room air, low flow O 2(L/min and % ), high flow O2(L/min 
and%), CPAP/BIPAP (FiO 2or %), mechanical ventilation (FiO 2or %), ECMO
Remde sivir (RDV; GS-5734T") 
Protocol GS-US-540-5774 
Gilead Sciences, Inc. 
Oxygenat ion: SpOi or Pa02 
Radiographic findings FINAL 
Amendment 2.0 
• Obta in blood samp les if not done in the preced ing 48 hours for creat inine, creatin ine 
clearance , ALT and AST 
• Pregnancy test (for women of childbear ing potent ial) 
• Record any serious adverse events and all adverse events related to protoco l-mandated 
procedures occurr ing after signing of the consent (or assent) fonn . 
Study subjects who qualify shou ld be immed iately random ized. Random ization and dosing 
shou ld occur on the same day if poss ible. 
6.2.2. Baseline /Day 1 A ssessments 
The following evaluations are to be comp leted at the Day 1 visi t. The invest igator must have 
confinned eligibility before proceed ing with random ization on the Day 1 visi t. If the screeni ng 
and Day 1 visi ts occur within 24 hours , no procedures need to be repeated . Participants must 
comp lete the following assessments before being administered study drug: 
• Phys ical exam ination includ ing, vital signs (heart rate, temperature , blood pressure , and body 
weight) 
• Documentat ion of respiratory status: 
Resp iratory rate 
Oxygen supp lementat ion: room air, l ow flow 0 2 (L/m in and%), high flow 0 2 (L/min 
and%), CPAP /BIPAP (Fi0 2 or%), mechan ical ventilation (Fi02 or%), ECMO 
Oxygenat ion: SpOi or Pa02 
Radiographic findings (if available) 
• Review AEs and document concom itant medicat ions 
• Obta in blood samp les for white blood cell count , hemog lobin and/or hematocr it, pl atelets, 
creat inine and creat inine clearance , glucose , total bilirubin, ALT, AST 
I 
• SARS-CoV-2 Testing: Collect nasopharyngea l swab samp le for subjects/sites partic ipating in 
this portion of the study 
• Review Ordinal Scale (Sect ion 6.9) 
CON FIDENTI AL Page 29 29 April 2020 
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-540-5774 
Gilead Sciences, Inc. 
6.3. Daily Study Assessments (Days 2-14 ) FINAL 
Amendment 2.0 
The following evaluations are to be comp leted daily from Days 2 14 or until discharge 
whichever comes earlier: 
• Vi tal signs (heart rate, temperature, blood pressure), body weight (if available). 
• A symptom- directed (targeted) phys ical exam ination will be perfon n ed to evaluate for any 
possible adverse event 
• D ocumentat ion of respiratory status: 
Resp iratory Rate 
Oxygen supp lementat ion: room air, low flow 02 (L/m in and%), high flow 02 (L/min 
and%), CPAP /BIPAP (FiO2 or%), mechan ical ventilation (FiO2 or%), ECMO 
Oxygenat ion: Sp02 or PaO2 
Radiographic findings (if available) 
• SARS-CoV-2 testing results if available shou ld be reported 
• Review AEs and docum ent concom itant medicat ions 
• Review Ordinal Scale (Sect ion 6.9) 
6.4. Additional Assessments 
The following evaluations are to be comp leted at the following visits or m1til discharge, 
whichever comes earlier: 
• Safety laboratory tests (white blood cell count, hemoglob in and/or hematocr it, platelets, 
creat inine and creat inine clearance, glucose, total bilirubin, ALT, AST) are to be comp leted 
at Days 3, 5, 8, 10, and 14 
I 
• SARS-CoV-2 Testing: Collect nasopharyngea l swab samp le at Days 3, 5, 8, 10, and 14 for 
subjects/sites partic ipating in this portion of the study 
CONFIDENT IAL Page 30 29 April 2020 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 31 29 April 20206.5. Day 28 F ollow up Assessment (± 5 Days)
The following evaluations are to be completed if this visit is conducted in person. For 
participant s who have been discharged from hospital, the final evaluation can be made b y phone.
Only  AE and concomitant medication and ordinal scale (if discharged on or after Day  14)review
areto be completed if visit is conducted by  phone .
Physical e xamination andvital signs (heart rate, temperature, blood pressure)
Documentatio n of respiratory  status:
Respiratory  rate
Oxygen supplementation: room air, low flow O 2(L/min and % ), high flow O 2(L/min 
and%), CPAP/BIPAP (FiO 2or %), mechanical ventilation (FiO 2or %), ECMO
Oxygenation: SpO 2or Pa O2
Radiographic findings (if available)
Review AEs and 
document concomitant medications
Review the Ordinal Scale (Section 6.9). If subject was not discharged by  Day  14, any  change 
in category  and the date of any  change in category  from Day  14 to discharge (or Day  28) 
should be recorded
6.6. Clinical Laboratory Assessments
Clinical laboratory  assessments are required at screening, Day s 1, 3, 5, 8, 10, and 14 or until 
discharge ,whichever comes earlie r. Clinical laboratory  assessments at other day s may  be 
conducted if required b y clinical need or local practice. From Day  1 to Day 14, 
at specified 
timepoints , the sponsor will be provided with results for the following analy tescompleted b y 
local laborat ories : white blood cell count, hemoglobin and/or hematocrit, platelets , creatinine and 
creatinine clearance, glucose, total bilirubin, AL T, AST, and an y SARS -CoV -2 testing.
SARS -CoV -2 testing may  include quantitative reverse transcriptase pol ymerase chain reaction
(qRT-PCR
)to detect or quantify  SARS -CoV -2 or virus sequencing results. 
Additional SARS -CoV -2 testing may be conducted at selected sites in a subset of participants. At 
participating sites
, nasophary ngeal swab samples will be collected at Day s 1,3, 5, 8, 10, and 14 , 
sent to a central laboratory, and assay ed using qRT -PCR to quantify  SARS -CoV -2 viral load. 
Pretreatment and posttreatment samples with detectable SARS -CoV -2 may be sequenced for 
resistance monitoring of the viral poly merase gene.
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-540-5774 
Gilead Sciences, Inc. FINAL 
Amendment 2.0 
For all clini cal laboratory tests at Day 1, at least the most recent result before dosing shou ld be 
used. For other tests, preferab ly en ter all results if the most recent result before dosing is not 
poss ible. Wh en more than 1 result is available in a calendar day, at minimmn , results shou ld be 
reporte d as indicated in T able 1. All SARS-CoV-2 results shou ld be prov ided. 
Table 1. Data E ntry Re quir ements When Only One Result of M ultipl e Results 
Is Recorded for a Given Day 
Test Name Minimum Data to be R ecorded 
Alanine aminotransferase Highest result 
Aspartate aminotransferase Highest result 
Crea ti nine Highest result 
Glucose Lowest result (hypoglycemia) 
Highest result (hyperglycemia) if outside normal range 
Total bilirubin Highest result 
Hematocrit Lowest result 
Hemoglobin Lowest result 
Platelets Lowest result 
White Blood Cells Lowest result 
Creatinine Clearance (Cockcroft -Gault or Lowest result Schwarz preferred) 
6.7. Physical Examination 
A targete d phys ical examination in cluding vital signs (heart rate, respiratory rate, temperature, 
blood pressure, Sp0 2 or Pa02) shou ld be perfon ned at least daily. 
6.9. Ordin al Scale 
The ordinal scale is an assess ment of the clinical status at a given study day. Each day, the worst 
(ie, lowest ordinal) score from the prev ious day w ill be recor ded, i e, on D ay 3, the lowest ordinal 
score from Day 2 is obta ined and recor ded for Day 2. The scale is as follows: 
1) D eath 
CONFI DENT IAL Page 32 29 April 2020 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 33 29 April 20202) Hospitalized, on invasive mechanical ventilation or ECMO
3)Hospitalized, on non-invasive ventilation or high flow ox ygen devices
4)Hospitalized, requiring low flow supplemental oxygen
5)Hospitalized, not requiring supplemental ox ygen -requiring ongoing medical care 
(COVID -19 related or otherwise)
6)Hospitalized, not re quiring supplemental ox ygen - no longer requires ongoing medical care 
(other than per protocol RDV administration)
7)Not hospitalized
6.10. Post-treatment Assessments
No assessments are required after Day  28.
6.11. Assessments for Early Discontinuation from Study
If a subject discontinues study  dosing (for example, as a result of an AE or clinically  significant 
laboratory  abnormality ), every  attempt should be made to keep the subject in the study  and 
continue to perform the required stud
y-related follow -up and procedure s (see Section 3.5, 
Discontinuation Criteria
). If this is not possible or acceptable to the subject or investigator, the 
subject may  be withdrawn from the study .
6.11.1. Criteria for Discontinuation of Study Treatment
Study  medication may  be discontinued in the following instances:
Discharge from the hospital/institution
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree. Following resolution of intercurrent illness, the subject 
may resume study  dosing at the discretion of the investigator.
Unacceptable toxicity , ortoxicity  that, in the judgment of the investigator, compromises the 
ability  to continue study -
specific procedures or is considered to not be in the subject’s best 
interest
Subject request to discontinue for an y reason
Subject noncompliance
Pregnancy  during the study ; refer to Appendix 3
Discontinuation of the study  at the request of Gilead, a regulatory  agency  or an IRB or IEC
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-540-5774 
Gilead Sciences, Inc. 
6.12. End of Study 
The end of the study w ill be the last participant's last observat ion ( or visit). 
6.13. Post Study Care FINAL 
Amendment 2.0 
The long-ten n care of the participant will remain the respo nsibility of their primary treat ing 
physic ian. Remdesivir is being supp lied with curat ive intent. There is no prov ision for post-stu dy 
availability. 
6.14. Sample Disposition and Storage (Non-PK Samples) 
Samples will be processe d and retained accor ding to local practi ce and the regu lations pertainin g 
to each institution. At participating sites, nasopharyngea l swab SARS-CoV-2 sam les will be 
collected and sent to Gilead or its researc h artner for additional vi rolo ic testin . 
• 
CONFI DENT IAL Page 34 29 April 2020 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 35 29 April 20207. ADVERSE EVENTS AND T OXICITY  MANAGEMENT
7.1. Definition sof Adverse Events and Serious Adverse Events
7.1.1. Adverse Events
An AEis an y untoward medical occurrence in a clinical study  subject administered a n 
investigational product ,which 
does not necessarily  have a causal relationship with th etreatment. 
An AE can therefore be any  unfavorable and/or unintended sign, s ymptom, or disease temporally  
associated with the use of a n investigational product, 
whether or not considered re lated to the 
investigational product. AEs may  also include pre treatment or posttreatment complications that 
occur as a result of protocol specified procedures or special situations ( Section 7.6).
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy ,tooth extraction, andtransfusion
.
The condition that ledto the procedure may  be an AEand must be reported.
Preexisting diseases ,conditions, or laboratory  abnormalities present or detected before the 
screening visit that donot worsen
Situations where an untoward medical occurrence has not occurred ( eg,hospitalization for 
elective surgery , social and/or conven ience admissions)
Overdose without clinical sequelae ( Section 7.6.1)
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. I t is considered to be pre existing and should be documented asmedical history .
Preexisting events or conditions that increase in severity  or cha nge in nature after the consent 
form is signed or as a consequence of participation in the clinical study  will be considered 
AEs
7.1.2. Serious Adverse Events
A SAE is defined as 
an event that, at any dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe)
In-patient hospitalization or prolongation of existing hospitalization
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 36 29 April 2020Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction: such events may  not be immediately  
life-threatening or result in d eath or hospitalization but may  jeopardize the subject or may  
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of m edically  important e vents include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; anddevelopment of drug dependency  or 
drug abuse. 
7.2.
Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessments .
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing t he relationship to study  
drug using clinical judgment and the following considerations:
No: Evidence exists that the AEhas an etiology  other than the study  drug . For SAEs, an 
alternative causality must be provided (eg, pre existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the AE may have been caused by  the study  drug .
It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of AE reporting. 
The relationship to study  procedures (eg, i nvasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the AE has an etiology  other than the study  procedure.
Yes: The AEoccurred as a result of protocol procedures (eg, venipun cture).
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 37 29 April 20207.2.2. Assessment of Severity
The severit y of AEs will be graded using the Division of AIDS (DAIDS) Table for Grading the 
Severity  of Adult and Pediatric Adverse Events, Version 2.1 dated July  2017. For each episode, 
the highest grade attained should be reported as defined in the grading scale. The DAIDS scale is 
available at the following location:
https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events 
7.3.1. Requirements for C ollection Prior to S tudy D rug Initiation
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
must be reported on the applicable eCRF s: all SAEs and AEs related to protocol -mandated 
procedures.
7.3.2. Adverse Events
Following initiation of study  medication, collect a ll AEs, regardless of cause or relationship, 
throughout the duration of the study , including the protocol -required post treatment follow -up 
period must be reported on the e CRF sas instructed.
All AEs and clinicall y significant laboratory abnormalities will be followed until resolution or 
stability  of the abnormality  has been demonstrated 
if possible. Gilead may request that certain 
AEs be followed bey ond the protocol -defined follow -up period.
7.3.3. Serious Adverse Events
All SAEs, regardless of cause or relationship, that occur safter the subject first consents to 
participate in the stud y (ie, signing the informed consent) and throughout the duration of the 
study , including the protocol -required post treatment follow -up period , must be reported on the 
applicable eCRFs and Pharmacovigilance an Epidemiology  (PVE) as instructed below in this 
section. This also includes any  SAEs resulting from protocol -associated procedures performed
after informed consent is signed.
Any SAEs and deaths that occur after the post-treatment follow -up visit but within 7- days of the 
last dose of study  drug , regardless of causalit y, should also be reported.
Investigators are not obligated to activel y seek SAEs after the protocol -defined follow -up perio d;
however, if the investigator learns of an y SAEs that occur after the protocol -defined follow - up 
period has concluded and the event is deemed relevant to the use of study  drug , the investigator
should prompt ly document and report the event to Gilead PVE .
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guidelines.  
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 38 29 April 20207.3.4. Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data on the applicable eCRF sand from there transmit the SAE 
information to Gilead PVE within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion g
uidelines.
If it i s not possible to record and submit the SAE information electronicall y, because the 
eCRF database cannot be accessed or is not available (including at study -start) , record t he 
SAE on the paper SAE reporting form and submit within 24 hours to:
Gilead PVE 
Email:  
or
Fax: 
As soon as it is possible to do so, any SAE reported via paper must be transcribed on the 
applicable eCRFs according to instructions and within the timelines outlined 
in the eCRF 
completion guidelines.
If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary.
For fatal or life -threatening events, copies of hospital case reports, autops y reports, and other 
documents are alsoto be submitted by email or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the tra ceability  of a document to the subject identifiers.
Additional information may  be requested t o ensure the timely  completion of accurate safet y 
reports.
Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s eCRF and the SAE narrative section of the Safet y Report 
Form eCRF .
7.4. Gilead Reporting R equirements
Depending on relevant local legislation or regulations, including the applicable USFDA Code of 
Federal Regulations, the European Union ( EU)Clinical Trials Directive (2001/20/EC) and 
relevant updates, and other country -specific legislation or regulations , Gilead may be required to 
expedite to worldwide regulatory  agencies reports of SAEs , serious adverse drug reactions 
(SADRs), or suspected u nexpected serious a dverse reactions (SUSARs). In accordance with the 
EU Clinical Trials Directive (2001/ 20/EC), Gilead or a specified designee will notify  worldwide 
regulatory  agencies and the relevant IECin concerned Member States of applicable SUSARs as 
outlined in current regulations.
PPD
PPD
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 39 29 April 2020Assessment of e xpectedness forSAEs will be determined by  Gilead using reference safety  
information specified in the i nvestigator’s brochure or relevant local label as applicable. 
All investigators will receive a safet y letter notifying them of relevant SUSAR reports associated 
with a ny study  drug. The investigator should notify  the IRB or IEC of SUSAR reports as soon as 
is practical, where this is required b y local regulatory agencies, and in accordance with the local 
institutional policy . 
7.5. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to study  drug interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x- rays, vital sign s) that are 
associated with signs and/or symptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.1 and 7.1.2. If the laboratory  
abnormality
 is part of a sy ndrome, record the s yndrome or diagnosis (eg, anemia), not the 
laboratory result (ie, decreased hemoglobin).
Laboratory  abnormalities that do not require medical intervention or action are generally  not 
considered AEs.
Severity  should be recorded and graded according to the DAIDS Table for Grading the Severity  
of Adult and Pediatric Ad verse Events, Version 2.1 dated July  2017. For AEs associated with 
laboratory  abnormalities, the event should be graded on the basis of the clinical severit y in the 
context of the underly ing conditions; this may  or may not be in agreement with the grading of 
the laboratory
 abnormality .
7.6. Special Situations Reports
7.6.1. Definitions of Special Situations
Special situation reports includ e all reports of medication error, abuse, misuse, overdose, 
occupational exposure, drug interactions, exposure via breastfeeding, unexpected benefit, 
transmission of infectious agents via the product ,counterfeit of falsified medicine, and 
pregnancy  regardless of an associated AE.
Medication error is an y unintentional error in the prescribing, dispensing , preparation for 
administration or administration of a n investigational product while the medication is in the 
control of ahealth care professi onal, patient ,or consumer. Medicat ion errors may  be classified as
a medication error without an AE, which includes situations of missed dose ; medica tion e rror 
with an AE ;
intercepted medication error;or potential medication error.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 40 29 April 2020Abuse is defined as persistent or sporadic intentional excessive use of a n investigational product 
by a subject.
Misuse is defined as an y intentional andinappropri ate useof an investigational product tha t is 
not in accordance with the protocol instructions or the local prescribing information
.
An overdose is defined as an accidental or intentional administration of a quantity  of an 
investigational product given per administration or cumulatively  which is above the maximum 
recommended dose as per protocol or in the product label ing(as it applies to the daily  dose of the 
subject in question). In cases of a discrepancy  in drug accountability , overdose will be 
established only  when it is clear that the subject has taken the excess dose(s). Overdose cannot 
be established when the subject cannot account for the discrepancy  except in cases in which the 
investigator has reason to suspect that the subject has taken t he additional dose(s).
Occupational exposure is defined as exposure to a n investigational product as a result of one’s 
professional or non- professional occupation.
Drug interaction is defined as a ny drug/drug, drug/f ood, or drug/device interaction.
Unexpec ted benefit is defined as an unintended therapeutic effect where the results are judged to 
be desirable and beneficial.
Transmission of infectious agents is defined as a ny suspected transmission of an infected agent 
through a Gilead investigational produc t.
Counterfeit or falsified medicine: An y investigational product with a false representation of: 
a)its identity , b) its source, or c) its history .
7.6.2. Instructions for Reporting Special Situations
7.6.2.1. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  drug and throughout the stud y, including the post study drug follow -up period, 
to Gilead PVE using the pregnancy  report form within 24 hours of becoming aware of the 
pregnancy .
Gilead PVE
Email:
or
Fax: 
Refer to Section 7.3and the eCRF completion guidelines for full instructions on the me chanism 
of pregnancy  reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
PPD
PPD
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 41 29 April 2020Any premat ure termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported within 24 hours as an 
SAE. The underl ying medical reason for this procedure should be recorded as the AEterm.
A spontaneous abortion is alway s considered to be an SAE and w ill be repor ted as described in 
Sections 7.3.2. Furthermore, an y SAE occurring as an adverse pregnancy  outcome post study
must be reported to Gilead PVE .
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy . The outcome should be reported to Gilead PVE using the pregnancy  outcome report 
form. If the end of the pregnancy  occurs after the study  has been completed, the outcome should 
be reported directl y to Gilead 
PVE . Gilead PVE contact information is as follows: email: 
 and f ax: 
Pregnancies of female partners of male stud y subjects exposed to Gilead study drugs must also 
be reported and relevant information should be submitted to Gilead PVE using the pregnancy  
and pregnancy  outcome forms within 24 hours. I f the end of the pregnancy occurs after the study  
has been completed, the outcome should be reported directl y to Gilead PVE , fax number 
 or email 
Refer to Appendix 3for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
7.6.2.2. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded 
to Gilead PVE within 24 hours of the investigator becoming aware of the situation. 
These reports must consist of situations that involve study  drug and/or Gilead concomitant 
medications
, but do not apply to non-Gilead concomitant medications.
Gilead PVE
Email:  
or
Fax: 
Special situations involving non-Gilead concomitant medications donot need to be reported on 
the spe cial situ ations report form; however, special situations that result in AEs due to a non-
Gilead concomitant medication, must be reported as an AE . 
Any inappropriate use of concomitant medications prohibited by  this protocol should not be 
reported as 
“misuse,” but may be more appropriately  documented as a protocol deviation.
Refer to Section 7.3and the eCRF completion guidelines for instructions on special situa tion 
reporting .
PPD
PPD
PPD
PPD
PPD
PPD
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 42 29 April 2020All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the sy mptoms and 
signs, clinical management, and outcome will be reported, when available.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 43 29 April 20208. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The purpose of this stud y is to provide RDV to participants with moderate COVID -19.
The primary  objective of this study  is as follows:
To evaluate th e efficacy of 2RDV regimens compared to standard of care (SOC), with 
respect to clinical status assessed by  a 7-point ordinal scale on Day  11
The secondary  objective of this study  is as follows:
To evaluate the safet y and tolerability  ofRDV compared to SOC
8.1.2. Primary Endpoint
The primary  endpoint of this study  is:
Clinical status assessed by a 7 -point ordinal scale on Day 11
8.1.3. Secondary Endpoints
The secondary  endpoint of this study  is:
The proportion of participants with treatment emergent adverse events 
8.1.4. Other Endpoints of Interest
Other endpoints of interest are:
The proportion of participants with negative SARS -CoV -2 PCR
Time to clinical improvement (day s): clinical improvement is defined as a ≥ 2-point 
improvement in clinical status (7-
point ordinal sca le) from Day  1 
Time to ≥ 1 -point improvement (day s) from baseline clinical status
Time to recovery : defined as an improvement in clinical status from a baseline score of 2 
through 5 to a score of 6 or 7, or an improvement from a baseline score of 6 to a s core of 7
Time to modified recovery : defined as an improvement in clinical status from a baseline 
score of 2 through 4 to a score of 5, 6, or 7, or an improvement from a baseline score of 5 to a 
score of 6 or 7, or an improvement from a baseline score of 6 to a score of 7
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 44 29 April 2020Time to room air: defined as an improvement in clinical status from a baseline score of 2 
through 4 to a score of 5, 6, or 7
Duration of ox ygen therapy (days)
Shift in ox ygen support status from baseline
Duration of hospitalization (day s)
All-cause mortalit y at Day 28
The proportion of participants in the Extension Treatment Group with treatment emergent 
adverse events
8.2. Planned Analyses
8.2.1. Interim Analysis
Prior to the final anal ysis, the primary  anal ysis of the primary  endpoint will be conducted, 
additional interim analy ses may  be conducted ,and the anal yses may  be submitted to regulatory  
agencies to seek guidance for the overall clinical development program or for other purposes.
8.2.1.1. DMC Analy sis
The DMC will review safety  data on a regular basis. T he DMC will review safet y and efficacy 
data at the time of the primary  anal ysis.
8.2.2. Primary Analysis
The primary analysis will be performed after all participants have completed Day 11 of Part A of 
the study  or prematurely  terminated from the study . 
8.2.3. Part A Analysis
The anal ysis for Part A subjects will be performed after all participants have completed Part A of 
the study  or prematurely  terminated from Part A of the study . 
8.2.4. Final Analysis
The final analy sis will be performed after all partic ipants have completed the study or 
prematurel y terminated from the study, outstanding data queries have been resolved or 
adjudicated as unresolvable, and the data have been cleaned and finalized .The final analy sis will 
summar ize results from Part B of the stud y.
CCII 
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-540-5774 
Gilead Sciences, Inc. 
8.3. 
8.3.1. 
8.3.1.1. Analysis Conventions 
Analysis Sets 
Efficacy FINAL 
Amendment 2.0 
The primary analysis set for efficacy analysis is defined as the Full Analysis Set (FAS), which 
will include a ll participants who (1) are randomized into Part A of the study and (2) have 
received at least 1 dose of study treatment if randomized to 1 of the RDV treatment groups . 
Participant s will be groupe d accor ding to the treatment to which they were randomized. 
8.3.1.2. Safety 
The primary analysis set for safety analyses is de fined as the Safety Analysis Set, which will 
includ e all partic ipants who (1) are randomized into the study and (2) have received at least 
1 dose of study treatment if randomized to 1 of the RDV treatment groups . Participant s will be 
groupe d accor ding to the treatment which they received. 
8.3.1.3. Extens ion Analysis Set 
The Extens ion Analysis Set will include participants who have received at least 1 dose of RDV 
in Extension Treatment Group . This analysis set will be used for both the safety and efficacy 
evaluations for participants enro lled in Part B. 
8.3.2. Data Handling Conventions 
Laborato ry data that are continuous in nature but are less than the lower limit of quant itation or 
above the upper limit of quant itation, will be imputed to the value of the lower or upper limit 
plus or minu s 1 si gnificant digit, respect ively ( eg, if the result of a continuous laboratory test is 
< 20, a value of 19 w ill be assigned). 
Missing data can have an impact upon the interpretat ion of the trial data. In genera l, values for 
missing data will not be imputed. However, a missing pre-treatment laboratory result would be 
treate d as nonna l (ie, no toxicity grade) for the laboratory abnorma lity summary. 
All available data for participants that do not comp lete the study w ill be inclu ded in data listings. 
CONFI DENT IAL Page 45 29 April 2020 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 46 29 April 20208.4. Demographic and Baseline Characteristics Analysis
Demographic and baseline measurements will be su mmarized using standard descriptive 
methods. Demographic summaries will include sex, race/ethnicity, and age. For ca tegorical 
demographic and baseline characteristics, a Cochran Mantel Haenszel 
test will be used to 
compare treatment groups. For continuous demographic and baseline characteristics, a Wilcoxon 
rank sum test will be used to compare treatment groups.
8.5. Efficacy Analysis
8.5.1. Primary Analysis
The primary  endpoint will be anal yzed using a proportional odds model including baseline 
clinical status as a covariate . Each RDV group will be compared to the SOC group. The null 
hypothesis being tested is whether the odds of improvement on the ordinal scale is the same for 
the SOC group and either RDV group (ie, whether the common odds ratio is equal to 1). The 
odds ratio and 95% confidence interval for each comparison will be provided. 
The proportion of subjects in eac h category  will be summarized by  treatment group. The validity  
of the proportionality  assumption will be evaluated. 
If a participant is discharged prior to Day  11, the Day  11 ordinal scale category  is considered to 
be not hospitalized. If a participant dies prior to Day 11, the Day 11 ordinal scale category is 
considered to be death . Every  effort will be made to obtain clinical status data for all subjects 
prior to discharge. 
8.5.2.
Secondary Analyses
The secondary  endpoint of proportion of pa rticipants with treatment emergent AEs will be 
compared between each of the RDV groups and standard of care group in PartAusing a Fisher’s 
Exact test. The point estimates of the treatment differences and the associated 95% confidence 
intervals will be pr ovided. O ther endpoints of interest related to proportion of partic ipants will be 
compared between treatment groups in Part A using a chi -square test or Fisher’s Exact test. 
Efficacy  endpoints that are measured as time to first event will be compared betwe en treatment 
groups using a competing risk model (with death as the competing risk) and continuous 
endpoints will be compared between treatment groups using a Wilcoxon rank sum test or 
analysis of variance model.
The 7 -point ordinal scale of clinical status and other efficacy  endpoint of interest will be 
summarized descriptively for Part B.
Remdesivir (RDV; GS-5734 T") 
Protocol GS-US-540-5774 
Gilead Sciences, Inc. 
8.6. Safety Analysis FINAL 
Amendment 2.0 
All safety data collected on or after the random ization date through the Day 28 follow-up visit 
will be smmnariz ed by treatment group ( accord ing to the study drug received). Data for the 
pretreatment period will be included in data listings. Part A and Part B will be smmnariz ed 
separate ly. 
8.6.1. Extent of Exposure 
A partic ipant's extent of exposure to study drug data will be generated from the study drug 
administration data. Exposure data will be smmnariz ed by treatment group for the RDV groups . 
8.6.2. Adverse Events 
Clinical and laboratory AEs will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA). System Organ Class (SOC), High-L evel Group Tenn (HLGT) , 
High-Le vel Tenn (HLT) , Preferr ed Tenn (PT), and Lower- Level Tenn (LLT) will be attached to 
the clinical database . 
Events will be smmnariz ed on the basis of the date of onset for the event. A treatment-emergent 
AE will be defined as any AE that begins on or after the random ization date up to the date of last 
dose of study drug plus 30 days, or up to Day 28, whichever is the later date. 
Smmnar ies (number and percentage of partic ipants) of treatment-emergent adverse events 
(TEAE s) (by SOC, and PT) will be provided by treatment group . 
8.6.3. Laboratory Evaluations 
Selected laboratory data will be smmnariz ed using only observed data. Data and change from 
baseline at all schedu led time points will be smmnariz ed. 
Graded laboratory abnorma lities will be defined using the grading sche me in DAIDS Table for 
Grading the Sever ity of Adult and Pediatric Adverse Events, Vers ion 2.1 dated July 2017 . 
Incid ence of treatment-emergent laboratory abnonna lities, defined as values that increase at least 
1 toxic ity grade from baseline at any time post base line up to the end date of the study, will be 
smmnariz ed by treatment group . If baseline data are missing, then any graded abnonna lity 
(ie, at least a Grade 1) will be considered treatment-emergent. 
Laboratory abnonna lities that occur before the first dose of study drug or after the subject has 
been discont inued from treatment for more than 30 days will be included in a data listing. 
CONFI DENT IAL Page 47 29 April 2020 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 48 29 April 20208.8. Adjustment s for Multiplicity
The statistical analysis plan will include alpha spending considerations for the primary  endpoint. 
Noother 
adjustments for multiple comparisons are planned.
8.9. Sample Size
The sample size computation is based on an assumed distribution of the 7- point ordinal scale on 
Day 11 for the SOC treatment group . The odds ratio represents the odds of improvement in the
7-point ordinal scale for an RDV treatment group relative to the SOC treatment group. The 
sample size needed to detect a given odds ratio for a 1:1 randomization using a 2- tailed test at 
level α is given b y:
12(
 ∝/ +   ) /   (1 −       
   )
Where θ is the log odds rat io, ρiis the overall probability  (combined over both treatment groups) 
of being in the ith category  of the ordinal outcome, and z α /2 and z βare the 1 -α /2and β quantiles 
of the standard normal distribution {Whitehead 1993 }.
A sample size of 600 participants (200 in each group) achieves > 85% power to detect an odds 
ratio of 1.8 using a two -sided significance level of 0.05 for comparing eac h RDV group (n 200) 
to standard of care group (n 200) . In this sample size calculation, it is assumed that the 
probability  distribution of the ordinal scale at Day 11 for Treatment Group 3 is as follows:
1.Death, 0.5%
2.Hospitalized, on invasive mechanical ven tilation or ECMO, 2.5%
3.Hospitalized, on non-invasive ventilation or high flow ox ygen devices, 7%
4. Hospitalized, requiring low flow supplemental oxygen, 8%
5.Hospitalized, not requiring supplemental ox ygen -requiring ongoing medical care 
(COVID -19 related or otherwise), 15%
6.Hospitalized, not requiring supplemental ox ygen - no longer requires ongoing medical care 
(other than per protocol RDV administration), 27%
7.Not hospitalized, 40%
The sample size calculation was done using software PASS (Version 14.0) .
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 49 29 April 20208.10. Data Monitoring Committee
An external Independent Data Monitoring Committee (IDMC) includes independent experts that 
do not have direct involvement in the conduct of the study. The IDMC will review the progress of 
the study  and perform interim reviews of effica cy and safet y data, and provide recommendation 
to Gilead whether the nature, frequency , and severity  of adverse effects associated with study  
treatment warrant the early termination of the study  in the best interests of the participants, 
whether the stud y should continue as planned, or the study  should continue with modifications.
The IDMC’s specific activities will be defined by  a mutually  agreed charter, which will define 
the IDMC’s membership, conduct and meeting schedule.
While the IDMC will be asked to advise Gilead regarding future conduct of the study , including 
possible earl y study termination, Gilead retains final decision -making authority  on all aspects of 
the study .
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 50 29 April 20209. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study is conducted in accordance with ICH E6(R2)
addendum to its guideline for GCPandapplicable laws and regulations including the principles 
of the Declaration of Helsinki .
9.1.2. Financial Disclosure
The investig ator and subinvestigators will provide prompt and accurate documentation of their 
financial interest or arrangements with Gilead, or proprietary  interests in the investigational drug 
during the course of a clinical study . This documentation must be provided prior to the 
investigator’s (and an y subinvestigator’s) participation in the study . The investigator and 
subinvestigator agree to notify  Gilead of an y change in reportable interests during the stud y and 
for 1 year following completion of the study. Study complet ion is defined as the date when the 
last subject completes the protocol
-defined activities.
9.1.3. Institutional Review Board /Independent Ethics Committee Review and 
Approval
The investigator (or Gilead as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to an IRB/IEC . The investigator will not begin an y study subject activities 
until approval from the IRB/IEC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submit to and receiv e documented approval from 
the IRB/IE Cany modifications made to the protocol or any accompan ying material to be 
provided to the subject after initial IRB/IE C approval, with the exception of those necessary  to 
reduce immediate risk to study  subjects.
9.1.4. Infor med Consent (or Assent)
The investigator is responsible for obtaining written informed consent or assent (age ≥12 to <18, 
where locally  and nationally  approved) from each individual participating in this study  after 
adequate explanation of the aims, method s, objectives, and potential hazards of the study  before 
undertaking an y stud y-related procedures. The investigator must use the most current IRB -or 
IEC-approved consent form for documenting written informed consent. Each informed consent 
(or assent as applicable) will be appropriatel y signed and dated b y the subject or the subject’s 
legally  authorized representative and the person conducting the consent discussion, and also b y 
an impartial witness if required by  IRB or IECorlocal requirements.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 51 29 April 20209.1.5. Confident iality
The investigator must assure that subjects’ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only  an identification code and an y other 
unique identifier (s) as allowed by  local law (such as y earof birth) will be recorded on an y form 
or biological sample submitted to Gilead, I RB or IEC. No biological samples will be provided to 
Gilead or an y central laboratory  during this study . NOTE :The investigator must keep a 
screening log with details for al l subjects screened and enrolled in the study , in accordance with 
the site procedures and regulations.  Subject data will be processed in accordance with all 
applicable regulations.
The investigator agrees that all information received from Gilead, includi ng but not limited to the 
investigator ’sbrochure, this protocol, CRF /eCRF , the study  drug , and any  other study  
information, remain the sole and exclusive property of Gilead during the conduct of the study  
and thereafter. This information is not to be disc losed to an y third part y (except emplo yees or 
agents directl y involved in the conduct of the study or as required by law) without prior written 
consent from Gilead. The investigator further agrees to take all reasonable precautions to prevent 
the disclosur e by any em ployee or agent of the study  site to an y third party or otherwise into the 
public domain.
9.1.6. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study  data to be subsequently  verified. These documents should 
be classified into at least the following 2 categories: (1)investigator’s study file, and (2) subject 
clinical source documents.
The investigator’s stud y file will contain the protoco l/amendments, paper or electronic 
completed subject CRF s,IRB or IEC and governmental approval with correspondence, informed 
consent, drug records, staff curriculum vitae and authorization forms, and other appropriate 
documents and correspondence.
The requ ired source data should include sequential notes containing at least the following 
information for each subject:
Subject identification;
Documentation that subject meets eligibility  criteria, ie, medical history , phy sical 
examination, and confirmation of d
iagnosis (to support inclusion and exclusion criteria);
Documentation of the reason(s) a consented subject is not enrolled ;
Participation in study  (including study  number);
Study  discussed and date of informed consent;
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 52 29 April 2020Dates of all visits;
Documentation that protocol -specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of study  drug , including dates of dispensing and 
return;
Record of all AEs and other safety  parameters (start and end date, and including causality  
and severit y), and documentation that adequate medical care has been provided for an y AE;
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of study  completion and reason for earl y discontinuation, if it occurs .
All clinical study  documents must be retained b y the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing applica tion in 
an ICH region (ie, 
US, Europe, or Japan) and until there are no pending or planned marketing 
applications in an I CH region; or, if no application is filed or if the application is not approved 
for such indication, until 2 years after the investigat ion is discontinued and regulatory  authorities 
have been notified. Investigators may  be required to retain documents longer if specified by  
regulatory
 requirements, by  local regulations, or by  an agreement with Gilead. The investigator 
must notify  Gilead b efore destroy ing an y clinical study records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement a t the study  site for any  or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securel y awa y from the site so that they  can be returned sealed to the investigator 
in case of a n inspection . Whe n source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away  from the site.
9.1.7. Case Report Forms
For each subject consented, an eCRF casebook will be completed b y an authorized study staff 
member whose training for this function is completed in the electronic data capture
(EDC )system. The eCRF casebook will only  capture the data required per the protocol schedule 
of events and procedures. The Inclusion/Exclusion Criteria and Enrollment eCRFs should be 
completed only  after all data related to eligibility  have been received. Data entry  should be 
performed in accordance with the eCRF Completion Guidelines ( eCCGs) provided by  the 
Sponsor. Subsequent to data entry , a stud y monitor will perform source da ta verification (SDV) 
within the EDC sy stem. System -generated or manual queries will be issued in the EDC sy stem 
as data discrepancies are identified by  the monitor or Gilead staff, who routinely  review the data 
for completeness, correctness, and consiste ncy.The site investigator or site coordinator or other 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 53 29 April 2020designee is responsible for responding to the queries in a timely  manner, within the sy stem, 
either b y confirming the data as correct or updating the original entry, and providing the reason 
for the update (e.g. data entry  error). Original entries as well as any  changes to data fields will be 
stored in the audit trail of the sy stem. At a minimum, prior to any  interim time points or 
database lock (as instructed by  Gilead), the investigator will use his/her log in credentials to 
confirm that the forms have been reviewed, and that the entries accuratel y reflect the information 
in the source documents. At the conclusion of the study , Gilead will provide the site investigator 
with a read -only archive copy of the data entered by  that site. This archive must be stored in 
accordance with the records retention requirements outlined in Section 9.1.6 .
9.1.8. I nvestigator Inspections
The investigator will make available all source documents and other records for this study to 
Gilead’s appointed stud y monitors , to IRBs/IECs, or to regulatory  authority or health authorit y 
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
9.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, may  be 
made only  by Gilead. The investigator must submit a ll protocol modifications to the IRB/IEC in 
accordance with local requirements and receive documented IRB/ IECapproval before 
modifications can be implemented.
9.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory agency (ies). Gilead 
will ensure that the report meets the standards set out in the I CH Guideline for Structure and 
Content of Clinical Study Reports (I CHE3). Note that an abbreviated report may  be prepared in 
certain cases.
Investigators in this study  may  communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met:
The results of the stud y in their entiret y have been publicly disclosed b y or with the consent of 
Gilead in an abstract, manuscript, or presentation form or the stud y has been completed at all 
study  sites for at leas t 2 years.
The investigator will submit to Gilead any  proposed publication or presentation along with the 
respective scientific journal or presentation forum at least 30 day s before submission of the 
publication or presentation. 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 54 29 April 2020No such communication, presentation, or publication will include Gilead’s confidential 
information ( see Section 9.1.5).
The investigator will comply  with Gilead’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
9.3. Joint Inve stigator/Sponsor Responsibilities
9.3.1.
Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, eg, attendance at I nvestigator Meetings.  If required under the applicable statutory  and 
regulatory  requirements, Gilead will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including an y clinical study payments, meal, 
travel expenses or reimbursements, consulting fees, and an y other transfer of value.
9.3.2. Access to Information for Monitoring
The monitor is responsible for routine review of the CRF /eCRF at regular intervals throughout 
the study  to verify  adherence to the protocol and the completeness, consistency , and accuracy  of 
the data being entered on them. The monitor should have access to an y subject records needed to 
verify  the entries i n the CRF /eCRF . The investigator agrees to cooperate with the monitor to 
ensure that an y problems detected through any  type of monitoring (central, on site) are resolved.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of Gilead may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify  the Gilead medical monitor immediately . The investigator agrees to 
provide to re presentatives of a regulatory  agency  or Gilead access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both Gilead and the investigator reserve the right to terminate the study  at any  time. S hould this 
be necessary , both parties will arrange discontinuation procedures and notify  the subjects, 
appropriate regulatory  authorit ies, IRB/IECs. In terminating the stud y, Gilead and the 
investigator will assure that adequate consideration is given to t he protection of the subjects’ 
interests.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 55 29 April 202010. REFERENCES
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16:31-41.
De Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al. Prophy lactic and 
Therapeutic Remdesivir (GS-5734) Treatment in the Rhesus Macaque Model of 
MERS -CoV I nfection. PNAS Latest Articles 2020.
Sheahan TP, Sims AC, Graham RL, Menachery  VD, Gralinski LE, Case JB, et al. Broad -
Spectrum Antiviral GS -5734 I nhibits Both Epide mic and Zoonotic Coronaviruses. 
Science translational medicine 2017:1 -20.
Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparative Therapeutic 
Efficacy  of Remdesivir and Combination L opinavir, Ritonavir, and Interferon 
Beta Against MER S-CoV. Nature communications 2020;11:222.
TAMIFLU®, Genentech Inc. TAMIFLU® (oseltamivir phosphate) capsules for oral use, 
TAMIFLU® (oseltamivir phosphate) for oral suspension. U.S. Prescribing 
Information. South San Francisco, CA. Revised August.  2019:
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and Chloroquine Effectivel y 
Inhibit the Recently  Emerged Novel Coronavirus (2019- nCoV) In Vitro. Cell 
research 2020;30:269-71.
Whitehead J. Sample size calculations for ordered categorical data. Stat Med 1993;12 (24):2257-
71.
World Health Organisation (WHO). Coronavirus Disease 2019 (COVID -19) Situation Report -
34. 2020.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 56 29 April 202011. APPENDICES
Appendix 1. Investigator Signature Page
Appendix 2. Study Procedures Table
Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 57 29 April 2020Appendix 1. Investigator Signature Page
GILEAD SCIENCES, INC
.
333 LAKESIDE DRIVE
FOSTER CITY, CA 9440 4
STUDY ACKNOWLEDG MENT
A Phase 3 Randomized Study  to Evaluate the Safety  and Antiviral Activity  of Remdesivir 
(GS-5734TM) in Participants with Moderate COVID -19 Compared to Standard of Care Treatment
Protocol Amendment 2.0 29 April 2020
This protocol has been approved b y Gilead Sciences, Inc. The following signature documents 
this approval.
Signature
Date
INVESTIGATOR STATEMENT
I have read the protocol, including all appendices, and I agree that it contains all necessary  
details for me and m y staff to conduct this study as described. I will conduct this study  as 
outlined herein and will make a reasonable effort to comp lete the study  within the time 
designated.
I will provide all study  personnel under my  supervision copies of the protocol and access to all 
information provided b y Gilead Sciences, Inc. I will discuss this material with them to ensure 
that they  are fully  informed about the drugs and the study .
Principal I nvestigator Name (Printed) Signature
Date Site Number
29 April 2020
PPD
PPD
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 58 29 April 2020Appendix 2. Study Procedures Table
ScreeningBaseline / 
Day 1b Day 2 Day 3 Day 4 Day 5Days 6 
and 7Day 8 Day 9 Day 10Days 11, 
12 and 
13Day 14Day 28c
Follow -up
(± 5 days)
Written Informed Consent X
Medical History X
Physical Examination X X X X X X X X X X X X X
Height X
Vital SignsaX X X X X X X X X X X X X
Study  Laboratory Testing X X X X X X X
Respiratory  Status X X X X X X X X X X X X X
Ordinal Scale X X X X X X X X X X X X
Pregnancy Test X
Virologic TestingeX X X X X X
RDV Dosing for Group 1 X X X X X
RDV Dosing for Group 2 X X X X X X X X X
Adverse Events X X X X X X X X X X X X X
Concomitant Medications X X X X X X X X X X X X X
a Includes heart rate, respiratory rate, temperature, blood pressure, Sp O2, and body weight . Body weight collected on Screening and Day 1 and otherwise if available .
b Assessments need not be repeated if performed within 24 hours of screening procedures; data collection other than adverse events and concomitant medications should stop at 
Day 14 or discharge ,whichever is earlier.
c Day 28 evaluations completed if the vis it is conducted in person. Only adverse event and concomitant medications review completed if visit conducted by phone .
e Virologic (SARS CoV 2) testing for subjects/sites par ticipating in this portion of the study on Days 1, 3, 5, 8, 10, and 14 .
CCI
CCII 
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 59 29 April 2020Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Definitions
a.Definition of Childbearing Pot ential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medically
 documented ovarian failure. No documentation of Tanner 
stage will be required for people unless deemed prepubescent.
Women are considered to be in a postmenopausal state when they  are > 54 years of a ge with 
cessation of previously  occurring menses for > 12 months without an alternative cause.  In 
addition, women of an y age with amenorrhea of >12 months may  also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the p ostmenopausal range 
and they  are not using hormonal contraception or hormonal replacement therapy .
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpingectomy  in a female subject of an y age. Tubal ligation is not consi dered a method of 
permanent sterilization for the purposes of this study .
b.Definition of Male Fertility
For the purposes of this study , a male born subject is considered of fertile after the initiation of 
puberty  unless permanently  sterile b y bilateral orchidectomy  or medical documentation.
2)Contraception Requirements for Female Subjects
a.Study Drug Effects on Pregnancy and Hormonal Contraception
Data from nonclinical studies of RDV have demonstrated no adverse effect on fertility  or 
embry o-fetal developme nt. Remdesivir has not y et been studied in pregnant women. Before 
enrolling into studies with RDV
, women of childbearing potential must have pregnancy  testing 
performed at screening .
Available data indicate that RDV potentially  causes an interaction with h ormonal contraception 
that is considered of limited significance. Hormonal methods must be used with a barrier 
method.
Please refer to the latest version of the investigator’s brochure for additional information.
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 60 29 April 2020b.Contraception Requirements for Female Subje cts of Childbearing Potential
The inclusion of female subjects of childbearing potential requires using at least an acceptable 
effective contraceptive measure. They  must have a negative pregnancy  test at Screening. In the 
event of a delay ed menstrual period (over one month between mens truations), a pregnancy  test 
must be performed to rule out pregnancy . This is applicable also for women of childbearing 
potential with infrequent or irregular periods. They must also agree to one of the following from 
Screening until the last dose of the s tudy drug:  
Complete abstinence from intercourse of reproductive potential. Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifesty le.
Or
Consistent and correct use of 1 of the following m ethods of birth control listed below. 
Non-hormonal intrauterine device (IUD)
Hormonal IUD (must be used with a barrier method)
Tubal sterilization
Vasectom y in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Barrier methods 
■ Female barriers: Diaphragm with spermicide or Cervical cap with spermicide
■ Male barriers: Male condom (with or without spermicide)
Hormonal methods are restricted to drugs associated with the inhibition of ovulation. 
Each method must be used with a barrier method, preferabl y male condom. 
Hormonally -based contraceptives permitted for use in this protocol are as follows:
■Oral contraceptives (either combined or progesterone only )
■Injectable proges terone
■Subdermal contraceptive implant
■Transdermal contraceptive patch
■Contraceptive vaginal ring
Remdesivir (RDV; GS -5734™)
Protocol GS -US-540-5774 FINAL
Gilead Sciences, Inc. Amendment 2.0
CONFIDENTIAL Page 61 29 April 2020Contraceptive methods must be locally  approved to be permitted.
Female subjects must also refrain from egg donation and in vitro fertilization during treatmen t 
and until the last study  drug dose. 
Inclusion of methods of contraception in this list of permitted methods does not imply  that the 
method is approved in any  country  or region. Methods should only  be used if locally  approved.
3)Contraception Requirements for Male Subjects
During the study  male subjects with female partners of childbearing potential should use 
condoms when engaging in intercourse of reproductive potential.
4) Unacceptable Birth Control Methods
Birth control methods that are unacceptable inclu de periodic abstinence ( eg,calendar, ovulation, 
symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides onl y, and 
lactational amenorrhea method (LAM).  A Female condom and a male condom should not be 
used together.
5)Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study . Subjects who become pregnant or who suspect that they  are pregnant during the stud y 
must report the information to the investigator and discontinue study  drug immediately . Subjects 
whose partner has become pregnant or suspects she is pregnant during the study  must report the 
information to the investigator. Instructions for reporting pregnancy , partner pregnancy , and 
pregnancy  outcome are outlined in Section 7.6.2.1.